Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining

Jason T. Lewis, Rhett P. Ketterling, Kevin C. Halling, Carol Reynolds, Robert Brian Jenkins, Daniel W Visscher

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Fluorescence in situ hybridization (FISH) and immunohistochemical analysis for assessment of HER-2 status in breast carcinomas are discordant in a significant proportion of cases with equivocal (2+) immunostaining. To evaluate the role of intratumoral heterogeneity and degree of amplification, we performed additional HER-2 immunostains and FISH on tumor-bearing blocks from 20 invasive breast carcinomas with immunohistochemical scores of 2+ with gene amplification and in 18 cases without amplification. Of the amplified cases, 11 (55%) had a 3+ immunohistochemical score on at least 1 additional slide, 8 (40%) remained 2+, and 1 (5%) had a slide scored 1+. All cases rescored 3+ showed high-level amplification in original and repeated FISH; cases remaining 2+ had a heterogeneous FISH profile (low-level amplification or a mosaic mixture of high-level amplified and nonamplified cells) in original and repeated FISH. Of nonamplified cases, 13 (72%) had a 1+ score on at least 1 additional slide, 4 (22%) remained 2+, and 1 (6%) had 1 slide scored 3+. In the nonamplified cases, 17 (94%) showed no amplification in repeated FISH. Significant intratumoral heterogeneity and minimal (low-level) HER-2 amplification account for many breast cancers with 2+ HER-2 protein expression.

Original languageEnglish (US)
Pages (from-to)273-281
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume124
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Fluorescence In Situ Hybridization
Breast Neoplasms
Gene Amplification
Neoplasms
Proteins

Keywords

  • Amplification
  • Breast carcinoma
  • HER-2
  • Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. / Lewis, Jason T.; Ketterling, Rhett P.; Halling, Kevin C.; Reynolds, Carol; Jenkins, Robert Brian; Visscher, Daniel W.

In: American Journal of Clinical Pathology, Vol. 124, No. 2, 08.2005, p. 273-281.

Research output: Contribution to journalArticle

@article{6d62b588317946bfa1ce50bbe2d06345,
title = "Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining",
abstract = "Fluorescence in situ hybridization (FISH) and immunohistochemical analysis for assessment of HER-2 status in breast carcinomas are discordant in a significant proportion of cases with equivocal (2+) immunostaining. To evaluate the role of intratumoral heterogeneity and degree of amplification, we performed additional HER-2 immunostains and FISH on tumor-bearing blocks from 20 invasive breast carcinomas with immunohistochemical scores of 2+ with gene amplification and in 18 cases without amplification. Of the amplified cases, 11 (55{\%}) had a 3+ immunohistochemical score on at least 1 additional slide, 8 (40{\%}) remained 2+, and 1 (5{\%}) had a slide scored 1+. All cases rescored 3+ showed high-level amplification in original and repeated FISH; cases remaining 2+ had a heterogeneous FISH profile (low-level amplification or a mosaic mixture of high-level amplified and nonamplified cells) in original and repeated FISH. Of nonamplified cases, 13 (72{\%}) had a 1+ score on at least 1 additional slide, 4 (22{\%}) remained 2+, and 1 (6{\%}) had 1 slide scored 3+. In the nonamplified cases, 17 (94{\%}) showed no amplification in repeated FISH. Significant intratumoral heterogeneity and minimal (low-level) HER-2 amplification account for many breast cancers with 2+ HER-2 protein expression.",
keywords = "Amplification, Breast carcinoma, HER-2, Immunohistochemistry",
author = "Lewis, {Jason T.} and Ketterling, {Rhett P.} and Halling, {Kevin C.} and Carol Reynolds and Jenkins, {Robert Brian} and Visscher, {Daniel W}",
year = "2005",
month = "8",
doi = "10.1309/J9VX-ABUG-KC4Y-07DL",
language = "English (US)",
volume = "124",
pages = "273--281",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining

AU - Lewis, Jason T.

AU - Ketterling, Rhett P.

AU - Halling, Kevin C.

AU - Reynolds, Carol

AU - Jenkins, Robert Brian

AU - Visscher, Daniel W

PY - 2005/8

Y1 - 2005/8

N2 - Fluorescence in situ hybridization (FISH) and immunohistochemical analysis for assessment of HER-2 status in breast carcinomas are discordant in a significant proportion of cases with equivocal (2+) immunostaining. To evaluate the role of intratumoral heterogeneity and degree of amplification, we performed additional HER-2 immunostains and FISH on tumor-bearing blocks from 20 invasive breast carcinomas with immunohistochemical scores of 2+ with gene amplification and in 18 cases without amplification. Of the amplified cases, 11 (55%) had a 3+ immunohistochemical score on at least 1 additional slide, 8 (40%) remained 2+, and 1 (5%) had a slide scored 1+. All cases rescored 3+ showed high-level amplification in original and repeated FISH; cases remaining 2+ had a heterogeneous FISH profile (low-level amplification or a mosaic mixture of high-level amplified and nonamplified cells) in original and repeated FISH. Of nonamplified cases, 13 (72%) had a 1+ score on at least 1 additional slide, 4 (22%) remained 2+, and 1 (6%) had 1 slide scored 3+. In the nonamplified cases, 17 (94%) showed no amplification in repeated FISH. Significant intratumoral heterogeneity and minimal (low-level) HER-2 amplification account for many breast cancers with 2+ HER-2 protein expression.

AB - Fluorescence in situ hybridization (FISH) and immunohistochemical analysis for assessment of HER-2 status in breast carcinomas are discordant in a significant proportion of cases with equivocal (2+) immunostaining. To evaluate the role of intratumoral heterogeneity and degree of amplification, we performed additional HER-2 immunostains and FISH on tumor-bearing blocks from 20 invasive breast carcinomas with immunohistochemical scores of 2+ with gene amplification and in 18 cases without amplification. Of the amplified cases, 11 (55%) had a 3+ immunohistochemical score on at least 1 additional slide, 8 (40%) remained 2+, and 1 (5%) had a slide scored 1+. All cases rescored 3+ showed high-level amplification in original and repeated FISH; cases remaining 2+ had a heterogeneous FISH profile (low-level amplification or a mosaic mixture of high-level amplified and nonamplified cells) in original and repeated FISH. Of nonamplified cases, 13 (72%) had a 1+ score on at least 1 additional slide, 4 (22%) remained 2+, and 1 (6%) had 1 slide scored 3+. In the nonamplified cases, 17 (94%) showed no amplification in repeated FISH. Significant intratumoral heterogeneity and minimal (low-level) HER-2 amplification account for many breast cancers with 2+ HER-2 protein expression.

KW - Amplification

KW - Breast carcinoma

KW - HER-2

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=23044475881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044475881&partnerID=8YFLogxK

U2 - 10.1309/J9VX-ABUG-KC4Y-07DL

DO - 10.1309/J9VX-ABUG-KC4Y-07DL

M3 - Article

VL - 124

SP - 273

EP - 281

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -